{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T19:26:06Z","timestamp":1784921166581,"version":"3.55.0"},"reference-count":51,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","diabetesresearchclinicalpractice.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Diabetes Research and Clinical Practice"],"published-print":{"date-parts":[[2021,5]]},"DOI":"10.1016\/j.diabres.2021.108820","type":"journal-article","created":{"date-parts":[[2021,4,16]],"date-time":"2021-04-16T12:13:05Z","timestamp":1618575185000},"page":"108820","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":47,"special_numbering":"C","title":["The future of insulin therapy"],"prefix":"10.1016","volume":"175","author":[{"given":"Tim","family":"Heise","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.diabres.2021.108820_b0005","doi-asserted-by":"crossref","DOI":"10.1016\/j.diabres.2021.108816","article-title":"The evolution of insulin therapy","author":"Home","year":"2021","journal-title":"Diabetes Res Clin Pract"},{"issue":"6","key":"10.1016\/j.diabres.2021.108820_b0010","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1007\/s00125-007-0599-y","article-title":"Risk of hypoglycaemia in types 1 and 2 diabetes: effects of treatment modalities and their duration","volume":"50","author":"UK Hypoglycaemia Study Group","year":"2007","journal-title":"Diabetologia"},{"issue":"1","key":"10.1016\/j.diabres.2021.108820_b0015","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.pcd.2016.09.003","article-title":"Clinical inertia to insulin initiation and intensification in the UK: A focused literature review","volume":"11","author":"Khunti","year":"2017","journal-title":"Prim Care Diabetes"},{"issue":"9 Suppl 1","key":"10.1016\/j.diabres.2021.108820_b0020","doi-asserted-by":"crossref","first-page":"S38","DOI":"10.1016\/j.amjmed.2013.06.012","article-title":"Breaking down patient and physician barriers to optimize glycemic control in type 2 diabetes","volume":"126","author":"Ross","year":"2013","journal-title":"Am J Med"},{"issue":"1","key":"10.1016\/j.diabres.2021.108820_b0025","doi-asserted-by":"crossref","first-page":"75","DOI":"10.4158\/EP13090.RA","article-title":"Insulin stacking versus therapeutic accumulation: understanding the differences","volume":"20","author":"Heise","year":"2014","journal-title":"Endocr Pract"},{"key":"10.1016\/j.diabres.2021.108820_b0030","doi-asserted-by":"crossref","first-page":"236","DOI":"10.2337\/db20-236-OR","article-title":"Molecular and biological properties of insulin icodec, a new insulin analog designed to give a long half-life suitable for once-weekly dosing","volume":"69","author":"Nishimura","year":"2020","journal-title":"Diabetes"},{"key":"10.1016\/j.diabres.2021.108820_b0035","doi-asserted-by":"crossref","DOI":"10.1210\/jendso\/bvab048.672","article-title":"Basal Insulin FC (BIF), a novel insulin suited for once weekly dosing for the treatment of patients with diabetes mellitus","author":"Heise","year":"2021","journal-title":"J Endocr Soc"},{"key":"10.1016\/j.diabres.2021.108820_b0040","doi-asserted-by":"crossref","DOI":"10.1210\/jendso\/bvab048.903","article-title":"Preclinical characterization of once weekly basal insulin Fc (BIF)","author":"Moyers","year":"2021","journal-title":"J Endocr Soc"},{"issue":"1","key":"10.1016\/j.diabres.2021.108820_b0045","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1111\/1753-0407.12266","article-title":"Steady state is reached within 2\u20133 days of once-daily administration of degludec, a basal insulin with an ultralong duration of action","volume":"8","author":"Heise","year":"2016","journal-title":"J Diabetes"},{"issue":"Suppl. 1","key":"10.1016\/j.diabres.2021.108820_b0050","article-title":"Insulin icodec: an insulin analog suited for once-weekly dosing in type 2 diabetes","volume":"69","author":"H\u00f6velmann","year":"2020","journal-title":"Diabetes"},{"issue":"3","key":"10.1016\/j.diabres.2021.108820_b0055","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1111\/dom.12416","article-title":"Low within- and between-day variability in exposure to new insulin glargine 300 U\/ml","volume":"17","author":"Becker","year":"2015","journal-title":"Diabetes Obes Metab"},{"issue":"22","key":"10.1016\/j.diabres.2021.108820_b0060","doi-asserted-by":"crossref","first-page":"2107","DOI":"10.1056\/NEJMoa2022474","article-title":"Once-Weekly Insulin for Type 2 Diabetes without Previous Insulin Treatment","volume":"383","author":"Rosenstock","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.diabres.2021.108820_b0065","doi-asserted-by":"crossref","DOI":"10.2337\/dc20-2877","article-title":"Switching to Once-Weekly Insulin Icodec Versus Once-Daily Insulin Glargine U100 in Type 2 Diabetes Inadequately Controlled on Daily Basal Insulin: A Phase 2 Randomized Controlled Trial","author":"Bajaj","year":"2021","journal-title":"Diabetes Care"},{"key":"10.1016\/j.diabres.2021.108820_b0070","doi-asserted-by":"crossref","DOI":"10.2337\/dc20-2878","article-title":"A Randomized, Open-Label Comparison of Once-Weekly Insulin Icodec Titration Strategies Versus Once-Daily Insulin Glargine U100","author":"Lingvay","year":"2021","journal-title":"Diabetes Care"},{"key":"10.1016\/j.diabres.2021.108820_b0075","doi-asserted-by":"crossref","DOI":"10.1210\/jendso\/bvab048.916","article-title":"Once Weekly Basal Insulin Fc (BIF) is safe and efficacious in patients with type 2 diabetes mellitus (T2DM) previously treated with basal insulin","author":"Frias","year":"2021","journal-title":"J Endocr Soc"},{"issue":"3","key":"10.1016\/j.diabres.2021.108820_b0080","doi-asserted-by":"crossref","first-page":"E206","DOI":"10.1152\/ajpendo.00406.2014","article-title":"Comparison of the physiological relevance of systemic vs. portal insulin delivery to evaluate whole body glucose flux during an insulin clamp","volume":"308","author":"Farmer","year":"2015","journal-title":"Am J Physiol Endocrinol Metab"},{"issue":"7","key":"10.1016\/j.diabres.2021.108820_b0085","doi-asserted-by":"crossref","first-page":"e126974","DOI":"10.1172\/jci.insight.126974","article-title":"Targeting insulin to the liver corrects defects in glucose metabolism caused by peripheral insulin delivery.","volume":"5","author":"Edgerton","year":"2019","journal-title":"JCI Insight"},{"issue":"11","key":"10.1016\/j.diabres.2021.108820_b0090","doi-asserted-by":"crossref","first-page":"3946","DOI":"10.2337\/db14-0266","article-title":"Changes in glucose and fat metabolism in response to the administration of a hepato-preferential insulin analog","volume":"63","author":"Edgerton","year":"2014","journal-title":"Diabetes"},{"issue":"9","key":"10.1016\/j.diabres.2021.108820_b0095","doi-asserted-by":"crossref","first-page":"2609","DOI":"10.2337\/dc14-0210","article-title":"Basal insulin peglispro demonstrates preferential hepatic versus peripheral action relative to insulin glargine in healthy subjects","volume":"37","author":"Henry","year":"2014","journal-title":"Diabetes Care"},{"issue":"Suppl 2","key":"10.1016\/j.diabres.2021.108820_b0100","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1111\/dom.12753","article-title":"Reduced peripheral activity leading to hepato-preferential action of basal insulin peglispro compared with insulin glargine in patients with type 1 diabetes","volume":"18","author":"Mudaliar","year":"2016","journal-title":"Diabetes Obes Metab"},{"issue":"Suppl 2","key":"10.1016\/j.diabres.2021.108820_b0105","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/dom.12744","article-title":"Basal insulin peglispro: Overview of a novel long-acting insulin with reduced peripheral effect resulting in a hepato-preferential action","volume":"18","author":"Jacober","year":"2016","journal-title":"Diabetes Obes Metab"},{"issue":"11","key":"10.1016\/j.diabres.2021.108820_b0110","doi-asserted-by":"crossref","first-page":"2154","DOI":"10.2337\/dc19-0152","article-title":"Divergent hypoglycemic effects of hepatic-directed prandial insulin: A 6-month phase 2b study in type 1 diabetes","volume":"42","author":"Klonoff","year":"2019","journal-title":"Diabetes Care"},{"issue":"Suppl. 1","key":"10.1016\/j.diabres.2021.108820_b0115","article-title":"Hepatic insulin delivery to minimize hypoglycemic events in persons with type 1 diabetes: the OPTI-1 study","volume":"69","author":"Bode","year":"2020","journal-title":"Diabetes"},{"issue":"3286","key":"10.1016\/j.diabres.2021.108820_b0120","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1136\/bmj.2.3286.1204","article-title":"Insulin in alcoholic solution by the mouth","volume":"2","author":"Harrison","year":"1923","journal-title":"Br Med J"},{"issue":"6","key":"10.1016\/j.diabres.2021.108820_b0125","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.2337\/dc09-1807","article-title":"Oral insulin: a comparison with subcutaneous regular human insulin in patients with type 2 diabetes","volume":"33","author":"Kapitza","year":"2010","journal-title":"Diabetes Care"},{"issue":"1","key":"10.1016\/j.diabres.2021.108820_b0130","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1002\/cpdd.730","article-title":"Pharmacokinetics and pharmacodynamics of insulin tregopil in relation to premeal dosing time, between meal interval, and meal composition in patients with type 2 diabetes mellitus","volume":"9","author":"Khedkar","year":"2020","journal-title":"Clin Pharmacol Drug Dev"},{"issue":"11","key":"10.1016\/j.diabres.2021.108820_b0135","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1007\/s40262-019-00772-2","article-title":"The effect of food intake on the pharmacokinetics of oral basal insulin: A randomised crossover trial in healthy male subjects","volume":"58","author":"Halberg","year":"2019","journal-title":"Clin Pharmacokinet"},{"issue":"3","key":"10.1016\/j.diabres.2021.108820_b0140","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1177\/1932296814529988","article-title":"Oral insulin reloaded: a structured approach","volume":"8","author":"Zijlstra","year":"2014","journal-title":"J Diabetes Sci Technol"},{"issue":"8","key":"10.1016\/j.diabres.2021.108820_b0145","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1111\/j.1463-1326.2010.01213.x","article-title":"A dose range finding study of novel oral insulin (IN-105) under fed conditions in type 2 diabetes mellitus subjects","volume":"12","author":"Khedkar","year":"2010","journal-title":"Diabetes Obes Metab"},{"issue":"3","key":"10.1016\/j.diabres.2021.108820_b0150","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1111\/cts.12609","article-title":"Impact of insulin tregopil and its permeation enhancer on pharmacokinetics of metformin in healthy volunteers: randomized, open-label, placebo-controlled","volume":"12","author":"Khedkar","year":"2019","journal-title":"Crossover Study Clin Transl Sci"},{"issue":"3","key":"10.1016\/j.diabres.2021.108820_b0155","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/S2213-8587(18)30372-3","article-title":"Efficacy and safety of oral basal insulin versus subcutaneous insulin glargine in type 2 diabetes: a randomised, double-blind, phase 2 trial","volume":"7","author":"Halberg","year":"2019","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"1","key":"10.1016\/j.diabres.2021.108820_b0160","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1021\/acs.jmedchem.0c01576","article-title":"Engineering of orally available, ultralong-acting insulin analogues: discovery of OI338 and OI320","volume":"64","author":"Kjeldsen","year":"2021","journal-title":"J Med Chem"},{"issue":"467","key":"10.1016\/j.diabres.2021.108820_b0165","doi-asserted-by":"crossref","first-page":"eaar7047","DOI":"10.1126\/scitranslmed.aar7047","article-title":"Transcellular stomach absorption of a derivatized glucagon-like peptide-1 receptor agonist","volume":"10","author":"Buckley","year":"2018","journal-title":"Sci Transl Med"},{"issue":"6427","key":"10.1016\/j.diabres.2021.108820_b0170","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1126\/science.aau2277","article-title":"An ingestible self-orienting system for oral delivery of macromolecules","volume":"363","author":"Abramson","year":"2019","journal-title":"Science"},{"key":"10.1016\/j.diabres.2021.108820_b0175","doi-asserted-by":"crossref","first-page":"101107","DOI":"10.1016\/j.molmet.2020.101107","article-title":"Review: Glucose-sensitive insulin","author":"Hoeg-Jensen","year":"2021","journal-title":"Mol Metab"},{"issue":"4423","key":"10.1016\/j.diabres.2021.108820_b0180","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1126\/science.505005","article-title":"A glucose-controlled insulin-delivery system: semisynthetic insulin bound to lectin","volume":"206","author":"Brownlee","year":"1979","journal-title":"Science"},{"issue":"3","key":"10.1016\/j.diabres.2021.108820_b0185","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1016\/j.diabres.2009.11.014","article-title":"Time lag characterization of two continuous glucose monitoring systems","volume":"87","author":"Garg","year":"2010","journal-title":"Diabetes Res Clin Pract"},{"issue":"22","key":"10.1016\/j.diabres.2021.108820_b0190","doi-asserted-by":"crossref","DOI":"10.1002\/adhm.201700601","article-title":"Rational design of glucose-responsive insulin using pharmacokinetic modeling","volume":"6","author":"Bakh","year":"2017","journal-title":"Adv Healthc Mater"},{"issue":"5","key":"10.1016\/j.diabres.2021.108820_b0195","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1007\/s00125-021-05422-6","article-title":"\u2018Smart\u2019 insulin-delivery technologies and intrinsic glucose-responsive insulin analogues","volume":"64","author":"Jarosinski","year":"2021","journal-title":"Diabetologia"},{"issue":"13","key":"10.1016\/j.diabres.2021.108820_b0200","doi-asserted-by":"crossref","first-page":"e1902004","DOI":"10.1002\/adma.201902004","article-title":"Glucose-responsive insulin and delivery systems: innovation and translation","volume":"32","author":"Wang","year":"2020","journal-title":"Adv Mater"},{"key":"10.1016\/j.diabres.2021.108820_b0205","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.jconrel.2017.01.043","article-title":"Glucose-responsive insulin release: Analysis of mechanisms, formulations, and evaluation criteria","volume":"263","author":"Yang","year":"2017","journal-title":"J Control Release"},{"issue":"1","key":"10.1016\/j.diabres.2021.108820_b0210","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1021\/acsnano.6b06892","article-title":"H2O2-responsive vesicles integrated with transcutaneous patches for glucose-mediated insulin delivery","volume":"11","author":"Hu","year":"2017","journal-title":"ACS Nano"},{"issue":"5","key":"10.1016\/j.diabres.2021.108820_b0215","doi-asserted-by":"crossref","first-page":"4194","DOI":"10.1021\/nn400630x","article-title":"Injectable nano-network for glucose-mediated insulin delivery","volume":"7","author":"Gu","year":"2013","journal-title":"ACS Nano"},{"issue":"11","key":"10.1016\/j.diabres.2021.108820_b0220","doi-asserted-by":"crossref","first-page":"eaaq0723","DOI":"10.1126\/sciadv.aaq0723","article-title":"Synthetic, \u201csmart gel\u201d provides glucose-responsive insulin delivery in diabetic mice","volume":"3","author":"Matsumoto","year":"2017","journal-title":"Sci Adv"},{"issue":"2","key":"10.1016\/j.diabres.2021.108820_b0225","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1002\/cpt.1215","article-title":"Clinical evaluation of MK-2640: an insulin analog with glucose-responsive properties","volume":"105","author":"Krug","year":"2019","journal-title":"Clin Pharmacol Ther"},{"issue":"2","key":"10.1016\/j.diabres.2021.108820_b0230","doi-asserted-by":"crossref","first-page":"299","DOI":"10.2337\/db17-0577","article-title":"Engineering glucose responsiveness into insulin","volume":"67","author":"Kaarsholm","year":"2018","journal-title":"Diabetes"},{"issue":"6","key":"10.1016\/j.diabres.2021.108820_b0235","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1002\/cpt.1729","article-title":"A Model-informed drug discovery and development strategy for the novel glucose-responsive Insulin MK-2640 enabled rapid decision making","volume":"107","author":"Visser","year":"2020","journal-title":"Clin Pharmacol Ther"},{"issue":"8","key":"10.1016\/j.diabres.2021.108820_b0240","doi-asserted-by":"crossref","first-page":"1608","DOI":"10.2337\/dbi20-0011","article-title":"Smarter Modeling to Enable a Smarter Insulin","volume":"69","author":"Taylor","year":"2020","journal-title":"Diabetes"},{"issue":"8","key":"10.1016\/j.diabres.2021.108820_b0245","doi-asserted-by":"crossref","first-page":"1815","DOI":"10.2337\/db19-0879","article-title":"Connecting rodent and human pharmacokinetic models for the design and translation of glucose-responsive insulin","volume":"69","author":"Yang","year":"2020","journal-title":"Diabetes"},{"issue":"1","key":"10.1016\/j.diabres.2021.108820_b0250","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1074\/jbc.M117.808626","article-title":"An ultra-stable single-chain insulin analog resists thermal inactivation and exhibits biological signaling duration equivalent to the native protein","volume":"293","author":"Glidden","year":"2018","journal-title":"J Biol Chem"},{"issue":"3","key":"10.1016\/j.diabres.2021.108820_b0255","first-page":"141","article-title":"Pancreatic extracts in the treatment of diabetes mellitus","volume":"12","author":"Banting","year":"1922","journal-title":"Can Med Assoc J"}],"container-title":["Diabetes Research and Clinical Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168822721001790?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168822721001790?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T19:16:52Z","timestamp":1759173412000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168822721001790"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5]]},"references-count":51,"alternative-id":["S0168822721001790"],"URL":"https:\/\/doi.org\/10.1016\/j.diabres.2021.108820","relation":{},"ISSN":["0168-8227"],"issn-type":[{"value":"0168-8227","type":"print"}],"subject":[],"published":{"date-parts":[[2021,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The future of insulin therapy","name":"articletitle","label":"Article Title"},{"value":"Diabetes Research and Clinical Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.diabres.2021.108820","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"108820"}}